

REGISTER
BY MAY 12 TO
SAVE \$700

AI PHARMA INNOVATION

July 25 – 27, 2017 Boston, MA
www.ai-pharma.com

**Strategically Adopt & Effectively
Apply AI to De-Risk Drug Discovery
& Development & Deliver Better &
More Cost Effective Medicines Faster**




Shahar Keinan
CSO
**Cloud
Pharmaceuticals**



David Christie
Vice President,
Research &
Development
Informatics
Amgen



Kaushik Raha
Head, Emerging
Analytics &
Advanced
Visualizations,
Data Sciences
Janssen



Jason Raines
Head, Biometrics
Data Sciences &
Operations
Biogen



**Ranga
Sarangarajan**
Senior Vice
President & CSO
BERG



Jeremy Sohn
Vice President,
Global Head of
Digital Business
Development &
Licensing
Novartis

WELCOME TO AI PHARMA INNOVATION 2017

Dedicated to Optimizing the Adoption and Application of AI in Pharma to Develop More Effective Medicines, Faster

ABOUT US

Unsustainable. The one word frequently used to describe traditional R&D. However, AI technologies are going to change that. AI is driving innovation in drug development, promising expedited timelines, identification of better drug candidates and ultimately a greater improvement of R&D productivity.

At this critical time when the worlds of AI and drug development are aligning, the AI Pharma Innovation Summit will showcase the **real world applications and adoption** of AI, machine learning, deep learning and cognitive approaches to bring value to future pipelines.

Discover the customized technology solutions you need and overcome the **cultural, technical integration and strategic challenges** in order to benefit from AI.

Attend to meet experts and leaders from large pharma, biotech, technology companies and academic institutions who are all capitalizing on AI technologies to **boost innovation and make smarter R&D decisions and investments.**

THE AI PHARMA INNOVATION 2017 EXPERIENCE:

Are you assessing the potential impact of AI in pharma? Is your AI program in its infancy or taking full flight? The AI Pharma Innovation Summit will provide you with a discussion led and collaborative platform to understand the fundamentals that are critical to ensure you harness and optimize AI to achieve sustainable levels of innovation.

Learn what AI actually is and what it means for the future of Pharmaceutical drug development

- Understand the differences and value of multiple AI algorithms with insight from **Numerate** and **Sanofi**
- Scope the potential benefit that these different algorithms can bring to numerous facets along the R&D pipeline to accelerate, de-risk and make drug discovery and development more cost effective

Discover how AI is being applied by fellow drug developers

- Access real world case studies and lessons learned from discovery through to clinical development from the likes of **Genentech, BERG, MSD, Biogen** and **Boehringer Ingelheim**
- Understand how AI can revolutionize the value of “big data”, unravel complexities in disease biology, optimize clinical trial operations and streamline the regulatory approval process

Understand which AI technology you need right now to succeed

- Assess and evaluate the right AI technology for your specific application and build the network to succeed
- Get the **Novartis** and **Takeda** perspectives on overcoming cultural and infrastructure barriers to streamline the integration and operation of an AI approach in your company

SPEAKER FACULTY



Ron Alfa
Vice President,
Discovery & Product
Recursion
Pharmaceuticals



Ryad Ali
Global Head,
Disruptive
Technologies
Novartis



Brandon Allgood
CTO
Numerate



David Christie
Vice President, Research
& Development
Informatics
Amgen



Shaun Comfort
Associate Director,
Senior Safety Science
Leader
Genentech



Giancarlo Crocetti
Associate Director,
IT-RDM Translational
Medicine
Boehringer Ingelheim



Jun Dong
Director, Global
Regulatory Affairs,
Development
& Information
Technology Services
Sanofi



Mark Gerstein
Professor, Biomedical
Informatics,
Molecular Biophysics,
Biochemistry &
Computer Science
Yale University



Chih-Ming Ho
CTO
KYAN Therapeutics



Shahar Keinan
CSO
Cloud
Pharmaceuticals



Guido Lanza
CEO
Numerate



Ray Liu
Senior Director &
Head, Statistical
Innovation &
Consultation
Takeda



Armaghan Naik
Director, Innovation
Sanofi



Kaushik Raha
Head, Emerging
Analytics & Advanced
Visualizations, Data
Sciences
Janssen



Jason Raines
Head, Biometrics Data
Sciences & Operations
Biogen



Leonardo Rodrigues
Associate Director,
Advanced
Analytics
BERG



Ranga Sarangarajan
Senior Vice
President & CSO
BERG



Ian Smith
Director, Scientific
Modelling & Real
World Data
MSD



Jeremy Sohn
Vice President,
Global Head of
Digital Business
Development &
Licensing
Novartis



Zeeshan Syed
Director, Clinical
Inference &
Algorithms
Program
**Stanford Health
Care**



Alex Zhavoronkov
CEO
Insilico Medicine

CONFERENCE DAY ONE WEDNESDAY, JULY 26

08.00 **Registration & Breakfast**

08.50 **Chair's Opening Remarks**



Ranga Sarangarajan
Senior Vice President &
CSO, **BERG**

Analyzing the Value & Scope of AI to Enhance Pharma Innovation

09.00 **DISCOVER: Understanding the Value of AI Application in Pharma R&D**

- Harnessing AI technology to elevate decision making across the R&D pipeline
- Separating the hype from reality: In the current climate where is the true value of AI technology in the pharmaceutical industry?
- Discussing how AI can deliver unique information in unique ways to provide valuable insight throughout R&D



David Christie
Vice President, Research
& Development
Informatics
Amgen

09.30 **DISCOVER: How AI can be Implemented in Key Areas of Failure Along the R&D Pipeline: A Technology Perspective**

- What is AI and what are the strengths and limitations?
- How to handle data and IT infrastructure to better leverage AI
- What are the cultural changes needed to allow AI to make the largest impact
- Understanding what is possible: Showcasing the value of AI technology to the pharmaceutical industry



Brandon Allgood
CTO
Numerate

10.00 **DISCUSS: How can AI Technology Accelerate, Cheapen and De-Risk R&D?**

- Understanding the capability of AI: Where is the ceiling?
- Keeping pace with developments: Discussing the most exciting industry advances
- Investigating the strengths and weaknesses of machine learning, deep learning and cognitive for R&D specific applications
- What novel questions can we now ask of our data using AI to advance R&D pipelines?



Guido Lanza
CEO
Numerate



Ian Smith
Director, Scientific
Modelling & Real
World Data
MSD



Armaghan Naik
Director, Innovation
Sanofi

10.45 **Speed Networking & Morning Refreshments**

Overcoming the Intersection of AI & Biology to Streamline the Application of AI in Pharma

11.45 **DISCOVER: Showcasing the Application of AI to Unravel Human Disease Complexity**

- Unlocking disease aetiology and pathogenesis through AI technology
- Discussing how AI will drive advances in solving fundamentals of biology
- Unlocking complexity: How AI can transform drug pipelines by elucidating the complexity of biology



Leonardo Rodrigues
Associate Director,
Advanced Analytics
BERG

12.15 **DISCUSS: Discussing the Collision of Two Powerhouse Industries to Harmonize AI Application in the Pharmaceutical Industry**

- Speaking two different languages: How can we streamline the biology and tech universes?
- Improving the tech understanding of the R&D process and the pharma understanding of limitations and opportunities for AI utilization
- How do you unlock biology using AI?
- How do you support discovery and development using AI?
- Investigating how AI can advance in silico modelling to improve pre-clinical translational modelling



Leonardo Rodrigues
Associate Director,
Advanced Analytics
BERG

13.00 **Networking Lunch**

Adoption & Acceptance: Key Cultural Challenges in the Integration of AI in Pharma

14.00 **DISCOVER: Pharma the Sloth - Accelerating the Integration of AI into Pharmaceutical DNA**

- Building up the capability to adopt, integrate and execute AI programs in R&D
- Driving strategic buy-in into AI technology
- How do we marry the rigidity of pharma R&D with the disruptiveness of AI technology to drive innovation from drug discovery through to clinical development?



Jeremy Sohn
Vice President, Global
Head of Digital Business
Development &
Licensing
Novartis

14.30 **ROUNDTABLE DEBATE: Overcoming Fear in the Cultural Adoption of AI Along Pharma R&D**

- Strategies for integrating AI into the standard R&D paradigm
- How to best change cultural influences to expedite the adoption of AI in pharma



14.45 **DISCUSS: Revolutionizing Pharmaceutical Culture and Process Towards the Integration of AI**

- Overcoming the cultural fear of AI adoption: Why does this exist and how do we combat it?
- How do we make the integration of AI technology smooth and seamless?
- How can we better align data science, IT, computational, modelling and traditional R&D functions to improve the implementation of AI technology?
- Building a data science function for AI from scratch: What are the do's and don'ts for success?
- A skills agenda - How do we attract more of the right talent to pharma?
- Do we have enough data science/computational specialists at the appropriate positions within pharma?
- Accelerating the integration of programmers and data scientists into pipeline and workflows



Jeremy Sohn
Vice President, Global
Head of Digital Business
Development &
Licensing
Novartis



Ray Liu
Senior Director & Head,
Statistical Innovation &
Consultation
Takeda



Ryad Ali
Global Head, Disruptive
Technologies
Novartis

15.30 **Afternoon Refreshments**

16.00 **AI Pharma Innovation Breakout Roundtables**

Our breakout roundtables will allow you to have more intimate discussions with AI and pharma leaders around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

1

What is pre-competitive and competitive in the AI space? Where will we benefit most from collaboration?



2

How do you build a business model based on AI technology in the pharma space?

Brandon Allgood, CTO,
Numerate
Guido Lanza, CEO
Numerate



3

Algorithms and architecture:
Comparing the value of
different AI algorithms in R&D

Armaghan Naik, Director,
Innovation, **Sanofi**



4

The Bottleneck to
Innovation: Discussing the
regulatory acceptance for
AI technology in Pharma



17.00 **Chair's Closing Remarks**



Ranga Sarangarajan
Senior Vice President &
CSO, **BERG**

17.05 **End of Day One**

CONFERENCE DAY TWO THURSDAY, JULY 27

08.00 **Breakfast & Networking**

08.50 **Chair's Opening Remarks**



Ranga Sarangarajan
Senior Vice President &
CSO, **BERG**

Beyond the Hypothetical: Real World Impact of AI Implementation in R&D

09.00 **DISCOVER: Understanding How AI Can Actionably Benefit R&D to Bring Innovation to Arid Pipelines**

- Adapting the same algorithm for multiple parts of the R&D value chain
- Retrospective analysis of AI projects to understand shortcomings
- Will AI implementation translate into drug candidate success? How close are we to this goal?
- Harnessing AI for prediction, risk management and analytical modelling



Ron Alfa
Vice President, Discovery
& Product
**Recursion
Pharmaceuticals**

09.30 **DISCOVER: AI Opportunities in R&D**

- Understanding current data mining efforts in R&D
- Promising AI approach that will shorten or improve drug development
- Creating new opportunities in the identification of new therapies



Giancarlo Crocetti
Associate Director,
IT-RDM Translational
Medicine
Boehringer Ingelheim

10.00 **DISCOVER: Showcasing the Utility of AI in Early Stages of R&D to Prove This Disruptive Technology's Validity**

- Developing validated methods to showcase applicability of AI platforms
- Building a "disease-profile" and harnessing multi-object optimization tools to design best candidates
- Matching AI performance to human decision making to demonstrate the utility of AI platforms



Shahar Keinan
CSO
**Cloud
Pharmaceuticals**

10.30 **Morning Refreshments**

Harnessing Differential Data-Centric & Knowledge Driven Approaches for R&D Innovation

11.00 **DISCOVER: Cognitive Computing Technology Pilot**

- Today, developing regulatory intelligence from internal and external available regulatory information is very time-consuming and resource-demanding
- The pilot is to assess current cognitive computing (machine intelligence) technology feasibility and maturity to replace (even partially) the manual process to provide RI answers to ad-hoc requests
- Discussing and evaluating lessons learned



Jun Dong
Director, Global
Regulatory Affairs,
Development &
Information Technology
Services
Sanofi

11.30 **DISCOVER: The Low Hanging Fruit that No One Seems to See - Yet: Using AI to Dig Through Your Haystacks of Safety Data**

- Collecting and uniting siloed safety data
- Harnessing machine learning to unlock valuable insight into drug candidate safety data



Shaun Comfort
Associate Director,
Senior Safety Science
Leader
Genentech

12.00 **DISCOVER: Harnessing AI to Make Sense of Large, Complex Datasets and Re-Invigorate R&D Innovation**

- Discussing how we can utilize AI to reduce cost, reduce timelines and improve the value of "big data" mining
- Understanding machine learning techniques to help manage genomic "big data"
- Improving data integrity and security in a cloud based, AI strategy



Mark Gerstein
Professor, Biomedical
Informatics, Molecular
Biophysics, Biochemistry
& Computer Science
Yale University

12.30 **Networking Lunch**

13.30 **ROUNDTABLE DEBATE: Resourcing & Upscaling to Maintain Flexibility in the Application of AI in R&D**

- Discussing the architecture needed to implement cloud computing for supporting the upscale and execution of machine learning platforms
- Debating how to ensure the flexibility and applicability of AI algorithms to the variance of data types unique to different applications along the R&D pipeline: What are the unique considerations for AI use on preclinical modelling data compared to clinical patient data?



13.45 **DISCUSS: Marrying Machine Learning Platforms with R&D Data to Streamline the Application of AI Technology**

- Selecting the right data: What data for which applications?
- Discussing data sharing and ownership
- Investigating liability concerns around data sharing and the competitiveness of information derived from AI algorithmic approaches
- How can we work towards a unified solution that can generalize for multiple types of data?
- What does the perfect work flow and technology stack look like for pharma-centric AI application?
- Understanding the computing resources needed to effectively action AI for big data sets
- Discussing blockchain technology, its value, implementation and intersection with AI and data



Jun Dong
Director, Global Regulatory Affairs, Development & Information Technology Services
Sanofi



Kaushik Raha
Head, Emerging Analytics and Advanced Visualizations, Data Sciences
Janssen



Shahar Keinan
CSO
Cloud Pharmaceuticals

14.30 **Afternoon Refreshments**

Analyzing Collaboration, Commerciality & Future Directions to Advance the Integration of AI in Pharma

15.00 **ROUNDTABLE DEBATE: Developing the Perfect Pharma-Tech Collaboration to Create Fertile Soils for Future Growth of the Industry**

- The do's and don'ts of the future pharma-tech collaboration
- Debating how AI can facilitate a wider discussion around cross-industry collaboration to improve global R&D efforts
- Developing trust and transparency in the pharma industry to advance the collaborative application of AI



15.15 **DISCUSS: What's the Future for AI Application and Collaboration and What Can We do to Maximize the Chance of Success?**

- What does the partnering paradigm look like for AI and pharma companies?
- What does long term value and ROI look like to all stakeholders involved?
- What are the requirements for each stakeholder entering an R&D agreement?
- What are the future questions we want to be asking now of our data and where must we improve AI technology to be able to answer them?
- Replacing humans with machines: What does the future application of AI technology look like?
- An eye on the end goal: Discussing the impact of AI on patient healthcare



Shaun Comfort
Associate Director, Senior Safety Science Leader
Genentech



Chih-Ming Ho
CTO
KYAN Therapeutics

16.00 **Chair's Closing Remarks**



Ranga Sarangarajan
Senior Vice President & CSO, **BERG**

16.15 **Close of Day Two & End of Inaugural AI Pharma Innovation Summit 2017**



"ALL SPEAKERS WERE HIGHLY QUALIFIED AND THE PRESENTATIONS WERE INSIGHTFUL."

Margaret McDonald, Pfizer, Advanced Analytics Event Attendee 2017

PRE-CONFERENCE WORKSHOP DAY

TUESDAY, JULY 25

Workshop A 09:00-11:30

AI for Precision Medicine: Harnessing AI Technology to Provide More Granular and Valuable Insights on Patients and Healthcare

The whole industry is investing in the precision medicine approach as the healthcare paradigm shifts towards value and outcomes. More so than ever, developing a biomarker approach, stratifying responder populations and gaining insight into patient responses is essential. Our workshop leader Prof. Zeeshan Syed will lead in-depth discussion and debate on the following topics:

- Unlocking novel insights on patients to improve drug efficacy and success
- Understanding patient populations: What can AI tell us that traditional stratifying approaches are yet to uncover?
- Algorithmic responsibility: Who holds accountability for the downstream effects of AI based decision making?
- An eye downstream: Understanding how AI can revolutionize personalized medicine and patient care
- Discussing the application of machine learning in patient stratification, genomic analysis, population investigation and real world data
- How to best action smart learning algorithms to comb over a wealth of genetic data and find patterns and insights that are significant for human health

WORKSHOP MODERATOR:



Zeeshan Syed

Director, Clinical Inference & Algorithms Program
Stanford Health Care

Workshop B 12:00 - 14:30

A Fundamental Guide to the Application of AI in Clinical Trials to Reduce Failure Rates

The clinical landscape is littered with safety and efficacy failures across the board. With so much invested to drive candidates through the clinical pipeline, current failure rates are simply unsustainable. This intimate and informal workshop session will take a deeper look at how AI technology can be applied across clinical trials to expedite trial time and ultimately improve approval rates. Topics of discussion to include:

- Discussing trial optimization and how AI can improve failure rates in clinical trials
- Applying AI to clinical trial design and the analysis of clinical trial data
- Investigating the role of machine learning in patient stratification prediction, population and genomic analysis
- Machine learning for analysis of genomic and imaging data
- What insights can AI give us into clinical outcomes?
- Harnessing AI to validate the predictiveness of diagnostic testing in the clinic
- Manipulating clinical data with machine learning analytics to derive exclusion criteria for efficient and cost effective patient selection
- Understanding how AI can be used to mine data for clinical trial site selection to improve enrolment, retention and ease of access for relevant patient cohorts

WORKSHOP MODERATOR:



Jason Raines

Head, Biometrics Data Sciences & Operations
Biogen

Workshop C 15:00-17:30

A Fundamental Guide to the Application of AI in Drug Discovery to Uncover the Next Wave of Successful Future Candidates

This interactive workshop session will delve deeper into the multiple applications of AI algorithms in drug design and discovery. With so much at stake later down the R&D pipeline, it is essential that only the best candidates are identified to progress through the pre-clinical and clinical landscapes. Immerse yourself in discussion on the following topics:

- How do you support discovery using AI?
- Training neural networks to predict molecular structures
- Improving the scaling of drug discovery efforts by utilizing AI technology
- Discussing the application of AI for target and compound selection
- Predictive analytics for drug discovery target validation
- Discussing sophisticated predictive machine learning methods to improve the speed and efficiency of drug discovery process
- Developing computational AI methods for screening
- Harnessing AI platforms to correlate label drug use and medical events to identify suitable molecules for drug repurposing

WORKSHOP MODERATOR:



Alex Zhavoronkov

CEO
Insilico Medicine

WHAT YOU'LL EXPERIENCE AT AI PHARMA INNOVATION 2017

WHO WILL YOU MEET?



80+
ATTENDEES



7+
HOURS OF DEDICATED
NETWORKING



3
INTERACTIVE
WORKSHOPS


WHY ATTEND AI PHARMA INNOVATION 2017

Whilst AI is not a new concept, it has newly broken into the mainstream conscious of the pharma industry as it matures, proves tangible value and the technology itself catches up with human ambition. The question is not will AI be the future of the industry, but how will AI shape this future?


As with any disruptive technology of this stature, understanding how to adopt, apply and separate hype from reality is essential.

Attend AI Pharma Innovation to gain strategic and technical insight into where AI is being used in pharma. Find out about opportunities that exist now for AI in R&D, how to apply it and which algorithms are most applicable for different types of data. Explore the real world impact AI can have on improving, de-risking and expediting research and development.

EXPECTED ATTENDANCE



COMPANIES BY TYPE



ABOUT THE AGENDA

We believe in candid, open and collaborative discussion, so we've ripped up the traditional conference format and started from scratch. From looking through the agenda, you will have seen the following sessions:

DISCOVER SESSIONS: Hear case studies from those who are successfully applying and validating AI algorithms in their R&D pipelines.

DEBATE SESSIONS: In small breakout groups, get a deeper understanding of the key challenges, opinions and approaches in a collaborative and informal setting.

DISCUSS SESSIONS: Journey behind the headlines and ask questions to panels of industry leaders to help you move beyond the "what" to the "why" and the "how" so you're able to develop actionable takeaways for your AI strategy.

BECOME A COMMERCIAL PARTNER

Partner with the only pharma-centric meeting dedicated to tackling and overcoming key challenges in the adoption and application of AI along the R&D pipeline in order to increase drug development approval rates.

The AI Pharma Innovation Summit is a dedicated and unique forum for pharma and biotech drug developers rapidly seeking the right AI technology to help them resurrect their arid drug portfolios. If you've got the technology that our audience needs to hear about, we've got the platform and expertise to position you correctly in front of a receptive biopharma market.



LET'S TALK

Sam Sarwar

E: sam.sarwar@hansonwade.com

T: +1 212 537 5898

POPULAR SPONSORSHIP BENEFITS

-  30 Minute Data-Driven or Case Study Led Presentation
-  15 Minute Innovation Talk
-  Expert Panel Inclusion
-  Exhibition Booth
-  Facilitated Introductions
-  Advanced Viewing of Delegate List
-  Hosted Lunch or Drinks Reception
-  On-Site and Web Branding
-  Pre-Conference Marketing Campaign

THESE OPPORTUNITIES ALLOW YOU TO

BENEFIT FROM MARKET INTELLIGENCE

Hear how and where pharmaceutical giants are looking to adopt and apply AI, enabling to match your solutions accordingly.

POSITION YOURSELF AS AN INDUSTRY THOUGHT LEADER

Pharma doors are now open to the idea of integrating AI programs. At this juncture it is crucial to stand out from the crowd. Demonstrate your expertise through podium presentations, moderating panel discussions or interactive roundtables.

RAISE BRAND AWARENESS

Benefit from pre and post conference exposure to our AI community and increase market share through unique branding formats.

MEET AND NETWORK WITH INDUSTRY PIONEERS

With a room full of drug developers looking to see how they can effectively apply AI solutions, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.

GENERATE COMMERCIAL COLLABORATIONS

Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

READY TO REGISTER?

3 EASY WAYS TO BOOK



www.ai-pharma.com



register@hansonwade.com



+1 212 537 5898

**Register By
May 12 To
SAVE \$700**

SECURE YOUR PLACE

Ticket Type	Register & Pay By Friday May 12	Standard Rate
PLATINUM Conference & 3 Workshops	\$3496 Save \$700	\$4196 Save \$300
GOLD Conference & 2 Workshops	\$2997 Save \$700	\$3697 Save \$200
SILVER Conference & 1 Workshop	\$2498 Save \$700	\$3198
BRONZE Conference Only	\$1999 Save \$700	\$2699

Ticket Type	Standard Rate
3 WORKSHOPS	\$1497 Save \$300
2 WORKSHOPS	\$998 Save \$200
1 WORKSHOPS	\$599

GROUP DISCOUNTS*

10% discount
3 delegates

15% discount
4 delegates

20% discount
5 delegates

*Please note that group discounts are only valid when 3 or more delegates book and pay at the same time.

**Academics receive a 30% discount on pricing

VENUE

Hyatt Regency Boston
1 Ave de Lafayette, Boston, MA
02111, USA

For further information or assistance, please visit
www.boston.regency.hyatt.com/en/hotel/home

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH